Keng-Chang Tsai

List of Publications by Year
in descending order

73	2,041	236925 25	265206 42
papers	citations	h-index	g-index

75	75	75	3109
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blockade effect of avian-derived anti-VISTA antibodies on immunosuppressive responses. International Journal of Transgender Health, 2022, 15, 479-489.	2.3	0
2	A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomedicine and Pharmacotherapy, 2021, 133, 111037.	5.6	58
3	Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response. Experimental Animals, 2021, 70, 333-343.	1.1	2
4	Characterizing the structureâ€“activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase. RSC Advances, 2021, 11, 2453-2461.	3.6	1
5	Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. Frontiers in Microbiology, 2021, 12, 698365.	3.5	16
6	Pdia4 regulates Î²â€cell pathogenesis in diabetes: molecular mechanism and targeted therapy. EMBO Molecular Medicine, 2021, 13, e11668.	6.9	13
7	Isolation of anti-VEGF monoclonal antibodies with neutralizing effects from an Astragalus-induced immune antibody library. International Immunopharmacology, 2020, 88, 107007.	3.8	6
8	Astragalus membranaceusâ€“Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. BioMed Research International, 2020, 2020, 1-11.	1.9	8
9	Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors. Bioorganic Chemistry, 2020, 96, 103618.	4.1	12
10	Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent. ACS Omega, 2019, 4, 2387-2397.	3.5	6
11	Exploring the mode of action of inhibitors targeting the PhoP response regulator ofSalmonella entericathrough comprehensive pharmacophore approaches. RSC Advances, 2019, 9, 9308-9312.	3.6	2
12	Generation and characterization of avian-derived anti-human CD19 single chain fragment antibodies. Animal Biotechnology, 2019, 30, 293-301.	1.5	5
13	Peramivir conjugates as orally available agents against influenza H275Y mutant. European Journal of Medicinal Chemistry, 2018, 145, 224-234.	5.5	17
14	GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice. Toxicology and Applied Pharmacology, 2018, 357, 88-105.	2.8	16
15	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. European Journal of Medicinal Chemistry, 2018, 154, 314-323.	5.5	24
16	Proteinâ€“DNA complex-guided discovery of the antibacterial lead E1 for restoring the susceptibility ofKlebsiella Pneumoniaeto polymyxin B by targeting the response regulator PmrA. Chemical Communications, 2018, 54, 6372-6375.	4.1	6
17	Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope. Viral Immunology, 2018, 31, 492-499.	1.3	4
18	New Hirsutinolide-Type Sesquiterpenoids from Vernonia cinerea Inhibit Nitric Oxide Production in LPS-Stimulated RAW264.7 Cells. Planta Medica, 2018, 84, 1348-1354.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Oral administration of boschnaloside, a GLP-1 receptor activator from herbal medicine <i>Boschniakia rossica</i> (the northern groundcone), improved diabetic conditions and modulated incretin hormone levels in db/db mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-5-32.	0.0	0
20	Characterizing the structureâ€“function relationship reveals the mode of action of a novel antimicrobial peptide, P1, from jumper ant Myrmecia pilosula. Molecular BioSystems, 2017, 13, 1193-1201.	2.9	12
21	Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus. Organic and Biomolecular Chemistry, 2017, 15, 9910-9922.	2.8	11
22	Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms. PLoS ONE, 2016, 11, e0160315.	2.5	17
23	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 5297-5310.	6.4	31
24	Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO. Journal of Biomedical Science, 2016, 23, 27.	7.0	8
25	Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. Molecular BioSystems, 2016, 12, 2541-2551.	2.9	3
26	Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 265-271.	2.2	10
27	Sarkosyl-Induced Helical Structure of an Antimicrobial Peptide GW-Q6 Plays an Essential Role in the Binding of Surface Receptor OprI in Pseudomonas aeruginosa. PLoS ONE, 2016, 11, e0164597.	2.5	7
28	The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition. Drug Metabolism and Disposition, 2015, 43, 1100-1107.	3.3	12
29	Engineering a nanopore with co-chaperonin function. Science Advances, 2015, 1, e1500905.	10.3	34
30	Discovery of novel FFA4 (GPR120) receptor agonists with Î²-arrestin2-biased characteristics. Future Medicinal Chemistry, 2015, 7, 2429-2437.	2.3	21
31	Discovery of Highly Potent Tyrosinase Inhibitor, T1, with Significant Anti-Melanogenesis Ability by zebrafish in vivo Assay and Computational Molecular Modeling. Scientific Reports, 2015, 5, 7995.	3.3	131
32	Single chain antibody fragment with serine protease inhibitory property capable of neutralizing toxicity of Trimeresurus mucrosquamatus venom. Biochemical and Biophysical Research Communications, 2015, 460, 170-176.	2.1	3
33	Discovery of Potent Cysteine-Containing Dipeptide Inhibitors against Tyrosinase: A Comprehensive Investigation of 20 Ã— 20 Dipeptides in Inhibiting Dopachrome Formation. Journal of Agricultural and Food Chemistry, 2015, 63, 6181-6188.	5.2	31
34	Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metabolism and Pharmacokinetics, 2015, 30, 374-383.	2.2	11
35	Phage Displayâ€“Mediated Discovery of Novel Tyrosinase-Targeting Tetrapeptide Inhibitors Reveals the Significance of N-Terminal Preference of Cysteine Residues and Their Functional Sulfur Atom. Molecular Pharmacology, 2015, 87, 218-230.	2.3	25
36	Evaluation of the Antihyperuricemic Activity of Phytochemicals fromDavallia formosanaby Enzyme Assay and Hyperuricemic Mice Model. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-8.	1.2	6

#	Article	IF	Citations
37	Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 6647-6654.	3.0	18
38	Serendipitous Discovery of Short Peptides from Natural Products as Tyrosinase Inhibitors. Journal of Chemical Information and Modeling, 2014, 54, 3099-3111.	5.4	37
39	Tamiphosphor monoesters as effective anti-influenza agents. European Journal of Medicinal Chemistry, 2014, 81, 106-118.	5.5	25
40	Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: Selectivity, kinetic characterization, and molecular modeling. Toxicology and Applied Pharmacology, 2013, 272, 671-680.	2.8	40
41	Isolation, Characterization, and Molecular Modeling of a Rheumatoid Factor from a Hepatitis C Virus Infected Patient with SjÃ¶grenâ€™s Syndrome. Scientific World Journal, The, 2013, 2013, 1-11.	2.1	6
42	Metabolomics study of Buyang Huanwu Tang Decoction in ischemic stroke mice by 1H NMR. Metabolomics, 2012, 8, 974-984.	3.0	22
43	Protein-Protein Interaction Site Predictions with Three-Dimensional Probability Distributions of Interacting Atoms on Protein Surfaces. PLoS ONE, 2012, 7, e37706.	2.5	25
44	Prediction of Carbohydrate Binding Sites on Protein Surfaces with 3-Dimensional Probability Density Distributions of Interacting Atoms. PLoS ONE, 2012, 7, e40846.	2.5	25
45	Rationalization and Design of the Complementarity Determining Region Sequences in an Antibody-Antigen Recognition Interface. PLoS ONE, 2012, 7, e33340.	2.5	42
46	A Practical Synthesis of Zanamivir Phosphonate Congeners with Potent Anti-influenza Activity. Journal of the American Chemical Society, 2011, 133, 17959-17965.	13.7	83
47	How to Generate Reliable and Predictive CoMFA Models. Current Medicinal Chemistry, 2011, 18, 923-930.	2.4	30
48	Structure and Immunological Characterization of the Capsular Polysaccharide of a Pyrogenic Liver Abscess Caused by Klebsiella pneumoniae. Journal of Biological Chemistry, 2011, 286, 21041-21051.	3.4	62
49	Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorganic and Medicinal Chemistry, 2010, 18, 4074-4084.	3.0	57
50	A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. European Journal of Medicinal Chemistry, 2010, 45, 1544-1551.	5.5	65
51	Development of GlcNAc-Inspired Iminocyclitiols as Potent and Selective N-Acetyl-Î²-Hexosaminidase Inhibitors. ACS Chemical Biology, 2010, 5, 489-497.	3.4	39
52	Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers. QSAR and Combinatorial Science, 2009, 28, 59-71.	1.4	12
53	The first pharmacophore model for potent NF-ÎºB inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5665-5669.	2.2	10
54	Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq.. Biochemical and Biophysical Research Communications, 2009, 385, 230-235.	2.1	37

#	ARTICLE	IF	CITATIONS
55	A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. European Journal of Medicinal Chemistry, 2008, 43, 1603-1611.	5.5	20
56	Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorganic and Medicinal Chemistry, 2008, 16, 4652-4660.	3.0	68
57	The effect of different electrostatic potentials on docking accuracy: A case study using DOCK5.4. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3509-3512.	2.2	31
58	Factor Xa Active Site Substrate Specificity with Substrate Phage Display and Computational Molecular Modeling. Journal of Biological Chemistry, 2008, 283, 12343-12353.	3.4	25
59	Synthesis of Tamiflu and its Phosphonate Congeners Possessing Potent Anti-Influenza Activity. Journal of the American Chemical Society, 2007, 129, 11892-11893.	13.7	200
60	Structureâ€Based Design and Synthesis of Highly Potent SARSâ€CoV 3CL Protease Inhibitors. ChemBioChem, 2007, 8, 1654-1657.	2.6	33
61	Discovery of a Novel Family of SARS-CoV Protease Inhibitors by Virtual Screening and 3D-QSAR Studies. Journal of Medicinal Chemistry, 2006, 49, 3485-3495.	6.4	67
62	Supervised Feature Ranking Using a Genetic Algorithm Optimized Artificial Neural Network. Journal of Chemical Information and Modeling, 2006, 46, 1604-1614.	5.4	15
63	Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Main Protease. Journal of Medicinal Chemistry, 2006, 49, 5154-5161.	6.4	133
64	Construction of a 3D model of nattokinase, a novel fibrinolytic enzyme from Bacillus natto. Journal of Molecular Graphics and Modelling, 2005, 23, 373-380.	2.4	49
65	Pharmacophore identification of Î±1A-adrenoceptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 657-664.	2.2	34
66	Modeling Ligandâ€"Receptor Interaction for Some MHC Class II HLA-DR4 Peptide Mimetic Inhibitors Using Several Molecular Docking and 3D QSAR Techniques.. ChemInform, 2005, 36, no.	0.0	0
67	Modeling Ligandâ^'Receptor Interaction for Some MHC Class II HLA-DR4 Peptide Mimetic Inhibitors Using Several Molecular Docking and 3D QSAR Techniques. Journal of Chemical Information and Modeling, 2005, 45, 1343-1351.	5.4	17
68	Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochemical and Biophysical Research Communications, 2005, 332, 677-687.	2.1	22
69	A Ligand-Based Molecular Modeling Study on Some Matrix Metalloproteinase-1 Inhibitors Using Several 3D QSAR Techniques. Journal of Chemical Information and Computer Sciences, 2004, 44, 1857-1871.	2.8	18
70	A Ligand-Based Molecular Modeling Study on Some Matrix Metalloproteinase-1 Inhibitors Using Several 3D QSAR Techniques.. ChemInform, 2004, 35, no.	0.0	0
71	3D-QSAR studies on PU3 analogues by comparative molecular field analysis. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 731-734.	2.2	7
72	The pharmacophore hypotheses of IKr potassium channel blockers: novel class III antiarrhythmic agents. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4771-4777.	2.2	46

#	ARTICLE	IF	CITATIONS
73	Implementing the Fisher's Discriminant Ratio in ak-Means Clustering Algorithm for Feature Selection and Data Set Trimming. Journal of Chemical Information and Computer Sciences, 2004, 44, 76-87.	2.8	42